BofA moved to No Rating on Bluebird Bio (BLUE) after the company announced it has entered a definitive merger agreement under which Carlyle and SK Capital will acquire Bluebird Bio for about $30M in upfront cash, or $3 per share, in addition to $6.84 per share in a contingent value right.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLUE:
- Cautious Hold Rating for Bluebird Bio Amid Strategic Shift and Uncertain Sales Milestones
- Bluebird Bio trading resumes
- Bluebird Bio trading halted, volatility trading pause
- Bluebird Bio downgraded to Neutral from Outperform at Baird
- Morning Movers: Bluebird Bio shares tumble following take-private deal